← Russell 3000 cross-section

JANX Janux Therapeutics, Inc.

Trailing twelve months to 2026-06-30 · as filed 2026-08-06, not restated
Healthcare

Scale

Market cap
$1.2bn
Revenue TTM
$24m
Net income TTM
$-103m
Free cash flow
$-42m
Composite score
61.2
Sector rank
#1946

Valuation

P / E
EV / EBITDA
EV / sales
7.6
FCF yield
-3.64%
Earnings yield vs 10-yr
-13.64pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
-427.5%
EBITDA margin
-590.2%
ROE
-11.1%
ROIC
Revenue growth
5,367.0%

Insider activity, last 90 days

Net open-market
$-0.06m
Buyers
0
Sellers
1

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

In return, we are eligible to receive up to $500.5 million per target in upfront and milestone payments, plus royalties on sales of the products derived from the collaboration. The increase of $10.3 million was due to the execution of the BMS Agreement in January 2026 and the related revenue recognized based on the full-time equivalent hours and costs incurred in the performance of research services required under the BMS Agreement. …Janux Therapeutics, Inc., 10-Q, period ended 2026-06-30, filed 2026-08-06

Read the full passage →